[New anthracycline analogues in the treatment of lung cancer].
Doxorubicin is one of the most potent drugs for the treatment of small cell lung cancer (SCLC), but less potent for non-small eell lung cancer (NSCLC). The prevalent use of doxorubicin is limited by the development of cardiomyopathy. Therefore, TUT-7 SM-5887, and ME2303 have been under the clinical studies to find new anthracyclines with less cardiotoxicity and higher therapeutic indices not only for SCLC but also for NSCLC. The dose-limiting factor of these drugs determined in phase I studies was leukocytopenia. Phase II studies which are currently under way have indicated that SM-5887 is possibly most potent for the treatment of NSCLC, and that these drugs have less cardiotoxicity compared to the mother compound, doxorubicin.
Ueoka
H
H
Second Dept. of Internal Medicine, Okayama University Medical School, Japan.
Ohnoshi
T
T
Kimura
I
I
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D017290:Menogaril / Q000627:therapeutic use*
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; C059081:ME 2303; D004317:Doxorubicin; D017290:Menogaril; C055866:amrubicin